Why PCOS Is Being Renamed to PMOS (Polyendocrine Metabolic Ovarian Syndrome)

For decades, Polycystic Ovary Syndrome (PCOS) has been one of the most misunderstood diagnoses in women’s health. And now, after an international consensus process involving researchers, clinicians, and patients across multiple countries, experts are recommending a new name: PMOS, or Polyendocrine Metabolic Ovarian Syndrome.

At first glance, this might seem like semantics. But the name change reflects something much bigger. The term PCOS has always been misleading. Many women diagnosed with “polycystic ovaries” do not actually have ovarian cysts at all - or they do at the start and then they disappear as time goes on 🙋‍♀️. The “cysts” seen on ultrasound are usually immature follicles, not pathological cysts.

Meanwhile, many women with the condition have completely normal ovarian morphology on imaging. The old name also focused heavily on the ovaries, but we understand this condition affects far more than reproduction alone.

PMOS better reflects what is really happening in the body:

• metabolic dysfunction

• insulin resistance

• neuroendocrine disruption

• inflammation

• altered ovulation

• androgen excess

• and long-term cardiovascular and metabolic risk

The new proposed name acknowledges that this is not simply a “fertility condition” or an ovarian issue. It is a whole-body endocrine and metabolic condition that can affect the brain, skin, liver, cardiovascular system, mood, appetite regulation, thyroid, and energy production.

Importantly, the consensus group behind the name change also recognised that the old terminology has caused confusion, delayed diagnosis, stigma, and poor patient understanding. Many women have spent years believing they literally had “cysts on their ovaries” without ever being properly educated about the metabolic and hormonal drivers underneath their condition and symptoms.

This shift also reflects a broader movement in women’s health. We are finally starting to move away from oversimplified labels and toward a more accurate understanding of female physiology.

And that matters, because language shapes healthcare.

When a condition is framed purely as an ovarian problem, treatment often becomes reductionistic and just about shutting off the ovaries. But when we understand PMOS as a complex neuroendocrine and metabolic condition, it opens the door to deeper conversations and clinical outcomes around insulin signalling, stress physiology, inflammation, nutrition, sleep, movement, circadian rhythm, and long-term health outcomes.